MX348564B - Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos. - Google Patents

Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos.

Info

Publication number
MX348564B
MX348564B MX2014006057A MX2014006057A MX348564B MX 348564 B MX348564 B MX 348564B MX 2014006057 A MX2014006057 A MX 2014006057A MX 2014006057 A MX2014006057 A MX 2014006057A MX 348564 B MX348564 B MX 348564B
Authority
MX
Mexico
Prior art keywords
pancreatic islet
islet cells
protection
thcv
tetrahydrocannabivarin
Prior art date
Application number
MX2014006057A
Other languages
English (en)
Other versions
MX2014006057A (es
Inventor
Stott Colin
Cawthorne Michael
Wright Stephen
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2014006057A publication Critical patent/MX2014006057A/es
Publication of MX348564B publication Critical patent/MX348564B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere al fitocannabinoide tetrahidrocannabivarina (THCV) para usarse en la protección de células de los islotes pancreáticos. Preferiblemente, las células de los islotes pancreáticos que han de ser protegidas son células beta. Muy preferiblemente, la protección de las células de los islotes pancreáticos mantiene la producción de insulina a niveles que son capaces de controlar sustancialmente o mejorar el control de los niveles de glucosa en la sangre en un paciente.
MX2014006057A 2011-11-21 2012-11-20 Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos. MX348564B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1120066.4A GB2496687A (en) 2011-11-21 2011-11-21 Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
PCT/GB2012/052869 WO2013076471A1 (en) 2011-11-21 2012-11-20 Tetrahydrocannabivarin (thcv) for use in the protection of pancreatic islet cells

Publications (2)

Publication Number Publication Date
MX2014006057A MX2014006057A (es) 2014-08-21
MX348564B true MX348564B (es) 2017-06-20

Family

ID=45475480

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006057A MX348564B (es) 2011-11-21 2012-11-20 Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos.

Country Status (14)

Country Link
US (1) US20160243075A2 (es)
EP (2) EP2782568B1 (es)
JP (1) JP6338531B2 (es)
CN (1) CN103945841A (es)
AU (1) AU2013201809B2 (es)
BR (1) BR112014012159A2 (es)
CA (1) CA2856102A1 (es)
DK (1) DK2782568T3 (es)
ES (2) ES2560835T3 (es)
GB (2) GB2496687A (es)
MX (1) MX348564B (es)
PL (1) PL2782568T3 (es)
PT (1) PT2782568E (es)
WO (1) WO2013076471A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US10077453B2 (en) 2014-07-30 2018-09-18 President And Fellows Of Harvard College CAS9 proteins including ligand-dependent inteins
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
IL310721A (en) 2015-10-23 2024-04-01 Harvard College Nucleobase editors and their uses
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CA3032699A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
AU2017308889B2 (en) 2016-08-09 2023-11-09 President And Fellows Of Harvard College Programmable Cas9-recombinase fusion proteins and uses thereof
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
US11542496B2 (en) 2017-03-10 2023-01-03 President And Fellows Of Harvard College Cytosine to guanine base editor
CN110914426A (zh) 2017-03-23 2020-03-24 哈佛大学的校长及成员们 包含核酸可编程dna结合蛋白的核碱基编辑器
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
WO2019152736A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
CA3104916C (en) * 2018-06-07 2023-08-15 Ke Zhang Pharmaceutical composition for preventing diabetes and use thereof
CN110575447B (zh) * 2018-06-07 2022-11-29 汉义生物科技（北京）有限公司 一种用于防治糖尿病的药物组合物及其用途
US11040932B2 (en) 2018-10-10 2021-06-22 Treehouse Biotech, Inc. Synthesis of cannabigerol
CA3119102A1 (en) * 2018-11-09 2020-05-14 Agriculture Victoria Services Pty Ltd Cannabis plants with a cannabinoid profile enriched for cannabidiol and .delta.-9-tetrahydrocannabinol
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
EP4188363A1 (en) 2020-07-28 2023-06-07 Wsmef, Llc Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
CN113135885A (zh) * 2021-04-07 2021-07-20 上海同田生物技术有限公司 一种高速逆流色谱分离纯化四氢次大麻酚的方法
WO2024006896A1 (en) * 2022-06-29 2024-01-04 The Regents Of The University Of California Uses of hydrogenated cannabidiol (h4cbd) and advanced metabolic syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
US9168278B2 (en) * 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
WO2007032962A2 (en) * 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
WO2007035665A1 (en) * 2005-09-20 2007-03-29 Novartis Ag Use of a dpp-iv inhibitor to reduce hypoglycemic events
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen

Also Published As

Publication number Publication date
CN103945841A (zh) 2014-07-23
PL2782568T3 (pl) 2016-05-31
DK2782568T3 (en) 2016-02-08
AU2013201809B2 (en) 2015-04-23
WO2013076471A1 (en) 2013-05-30
AU2013201809A1 (en) 2013-06-06
GB2496761A (en) 2013-05-22
EP2782568B1 (en) 2015-10-28
GB201220874D0 (en) 2013-01-02
PT2782568E (pt) 2016-02-01
CA2856102A1 (en) 2013-05-30
JP6338531B2 (ja) 2018-06-06
EP2782568A1 (en) 2014-10-01
BR112014012159A2 (pt) 2017-05-30
EP3028697A1 (en) 2016-06-08
US20160243075A2 (en) 2016-08-25
MX2014006057A (es) 2014-08-21
GB2496687A (en) 2013-05-22
US20140335208A1 (en) 2014-11-13
US20160015682A2 (en) 2016-01-21
GB201120066D0 (en) 2012-01-04
ES2714350T3 (es) 2019-05-28
EP3028697B1 (en) 2018-12-26
ES2560835T3 (es) 2016-02-23
JP2014533680A (ja) 2014-12-15

Similar Documents

Publication Publication Date Title
MX348564B (es) Tetrahidrocannabivarina para usarse en la protección de células de los islotes pancreáticos.
IN2014DN09782A (es)
HK1214168A1 (zh) 通過控制血糖水平用於治療糖尿病及相關疾病的組合物、方法以及用途
EP2793932A4 (en) CTP-BASED INSULIN ANALOGUE FOR THE TREATMENT OF DIABETES
MY170713A (en) Treatment protocol of diabetes type 2
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
EP2903616B8 (en) Use of masitinib in combination with gemcitabine for treating a subgroup of patients suffering from pancreatic cancer
HK1202458A1 (en) Glucokinase activator compositions for the treatment of diabetes
MX343931B (es) Tratamiento de la esclerosis lateral amiotrofica con el uso de celulas derivadas del cordon umbilical.
IL236346A0 (en) Preparations containing non-multipurpose pancreatic progenitor cells and their uses for the treatment of insulin-dependent diabetes
WO2013078376A3 (en) Isoxazole treatments for diabetes
PH12014501646A1 (en) Substituted phenylazole derivative
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
WO2012123519A3 (en) Human insulin analogues and derivatives comprising cysteine substitutions
MX2014006990A (es) Tratamiento para diabetes tipo i y tipo ii.
MX2013011732A (es) Derivados de isoindolinona.
EP2813237A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES CONTAINING A SUPPRESSOR OF THE EXPRESSION OR ACTIVITY OF TENC1
MX354742B (es) Uso de compuestos de vanadio para mantener normaglucemia en un mamifero.
MX2013009456A (es) Compuestos de azufre aromaticos sustituidos y metodos para su uso.
EP2625270A4 (en) GLP-1 PROMOTER-MEDIATED INSULINE EXPRESSION FOR THE TREATMENT OF DIABETES
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
WO2011161295A3 (es) Uso de compuestos anticalcineurina para el tratamiento de patologías que cursan con neovascularización ocular
TN2010000408A1 (en) Thiazolyl-dihydro-indazoles
UA65038U (ru) Способ лечения больных послеродовыми психозами

Legal Events

Date Code Title Description
FG Grant or registration